Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 442

1.

Galectin-3 correlates with arrhythmogenic right ventricular cardiomyopathy and predicts the risk of ventricular -arrhythmias in patients with implantable defibrillators.

Oz F, Onur I, Elitok A, Ademoglu E, Altun I, Bilge AK, Adalet K.

Acta Cardiol. 2017 Jul 14:1-7. doi: 10.1080/00015385.2017.1335371. [Epub ahead of print]

PMID:
28705047
2.

Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future.

Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK.

Circulation. 2017 Jul 11;136(2):215-231. doi: 10.1161/CIRCULATIONAHA.116.027134. Review.

PMID:
28696268
3.

Impact of statin therapy on all-cause mortality and ICD interventions in heart failure patients - a systematic review.

Bazoukis G, Papadatos SS, Letsas KP, Pagkalidou E, Korantzopoulos P.

Acta Cardiol. 2017 Jul 7:1-6. doi: 10.1080/00015385.2017.1310562. [Epub ahead of print]

PMID:
28685653
4.

Sudden cardiac death in nonischemic cardiomyopathy: Refining risk assessment.

Zipse MM, Tzou WS.

J Cardiovasc Electrophysiol. 2017 Jul 3. doi: 10.1111/jce.13284. [Epub ahead of print] Review.

PMID:
28670752
5.

Devices for management of sudden cardiac death: Successes, challenges and perspectives.

Dagres N, Hindricks G.

Int J Cardiol. 2017 Jun 15;237:34-37. doi: 10.1016/j.ijcard.2017.03.053. Epub 2017 Mar 15.

PMID:
28385355
6.

Evidence of Cognitive Bias in Decision Making Around Implantable-Cardioverter Defibrillators: A Qualitative Framework Analysis.

Matlock DD, Jones J, Nowels CT, Jenkins A, Allen LA, Kutner JS.

J Card Fail. 2017 Mar 28. pii: S1071-9164(17)30089-1. doi: 10.1016/j.cardfail.2017.03.008. [Epub ahead of print]

PMID:
28363805
7.

Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate.

Barra S, Boveda S, Providência R, Sadoul N, Duehmke R, Reitan C, Borgquist R, Narayanan K, Hidden-Lucet F, Klug D, Defaye P, Gras D, Anselme F, Leclercq C, Hermida JS, Deharo JC, Looi KL, Chow AW, Virdee M, Fynn S, Le Heuzey JY, Marijon E, Agarwal S; French-UK-Sweden CRT Network.

J Am Coll Cardiol. 2017 Apr 4;69(13):1669-1678. doi: 10.1016/j.jacc.2017.01.042.

PMID:
28359511
8.

Long-Term Prognosis of Patients with an Implantable Cardioverter-Defibrillator in Korea.

Uhm JS, Kim TH, Kim IC, Park YA, Shin DG, Lim YM, Yu HT, Yang PS, Pak HN, Kang SM, Lee MH, Joung B.

Yonsei Med J. 2017 May;58(3):514-520. doi: 10.3349/ymj.2017.58.3.514.

9.

Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial.

Sapp JL, Parkash R, Wells GA, Yetisir E, Gardner MJ, Healey JS, Thibault B, Sterns LD, Birnie D, Nery PB, Sivakumaran S, Essebag V, Dorian P, Tang AS.

Circ Arrhythm Electrophysiol. 2017 Mar;10(3). pii: e004875. doi: 10.1161/CIRCEP.116.004875.

PMID:
28292754
10.

Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy.

Akoudad S, Dabiri Abkenari L, Schaer BA, Sticherling C, Levy WC, Jordaens L, Theuns DA.

Am J Cardiol. 2017 May 1;119(9):1414-1420. doi: 10.1016/j.amjcard.2017.01.035. Epub 2017 Feb 10.

PMID:
28267958
11.

Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.

Robinson VM, Bharucha DB, Mahaffey KW, Dorian P, Kowey PR; SHIELD-2 Investigators.

Am Heart J. 2017 Mar;185:43-51. doi: 10.1016/j.ahj.2016.10.025. Epub 2016 Nov 15.

13.

Arrhythmic risk stratification in heart failure: Time for the next step?

Gatzoulis KA, Sideris A, Kanoupakis E, Sideris S, Nikolaou N, Antoniou CK, Kolettis TM.

Ann Noninvasive Electrocardiol. 2017 Mar;22(2). doi: 10.1111/anec.12430. Epub 2017 Feb 3. Review.

PMID:
28252256
14.

Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials.

Wolff G, Lin Y, Karathanos A, Brockmeyer M, Wolters S, Nowak B, Fürnkranz A, Makimoto H, Kelm M, Schulze V.

Clin Res Cardiol. 2017 Jul;106(7):501-513. doi: 10.1007/s00392-017-1079-0. Epub 2017 Feb 17.

PMID:
28213711
15.
17.
18.

Primary Prevention of Sudden Cardiac Death With Device Therapy in Urban and Rural Populations.

Parkash R, Wightman H, Miles G, Sapp JL, Gardner M, Gray C, Brownell B, Giddens K, Rajda M.

Can J Cardiol. 2017 Apr;33(4):437-442. doi: 10.1016/j.cjca.2016.10.020. Epub 2017 Jan 17.

PMID:
28110802
19.

The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED).

Gold MR, Knops R, Burke MC, Lambiase PD, Russo AM, Bongiorni MG, Deharo JC, Aasbo J, El Chami MF, Husby M, Carter N, Boersma L.

Pacing Clin Electrophysiol. 2017 Jan;40(1):1-8. doi: 10.1111/pace.12994. Epub 2017 Jan 15.

PMID:
27943348
20.

Long-time "real-life" performance of the subcutaneous ICD in patients with electrical heart disease or idiopathic ventricular fibrillation.

Frommeyer G, Dechering DG, Kochhäuser S, Bettin M, Köbe J, Eckardt L, Reinke F.

J Interv Card Electrophysiol. 2016 Nov;47(2):185-188. Epub 2016 May 23.

PMID:
27217031

Supplemental Content

Loading ...
Support Center